Skip to content

Runzaoyin in the treatment of primary Sjogren's syndrome Clinical observation of spleen deficiency and fluid deficiency syndrome

Runzaoyin in the treatment of primary Sjogren's syndrome Clinical observation of spleen deficiency and fluid deficiency syndrome

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2200005628
Enrollment
Unknown
Registered
2022-02-09
Start date
2022-02-15
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

primary Sjogren's syndrome

Interventions

Test group:Runzaoyin granule,one sack/time,bid
control group:placebo(5%Runzaoyin component),one sack/time,bid

Sponsors

Xiyuan Hospital, Chinese Academy of traditional Chinese medical science
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: ? Meet the classification criteria of ACR and EULAR primary Sjogren's syndrome in 2016; ? Spleen deficiency and fluid deficiency syndrome conforming to the standard of TCM syndrome differentiation; ? Age 18-70 years; ? Informed and signed informed consent.

Exclusion criteria

Exclusion criteria: ? It belongs to secondary Sjogren's syndrome complicated with other connective tissue diseases (such as rheumatoid arthritis, systemic lupus erythematosus, ankylosing spondylitis, etc.); ? Women with family planning during pregnancy, lactation or observation; ? Allergic constitution or allergic to the drug components of the preparation; ? Patients with severe primary diseases such as heart, brain, liver, kidney and hematopoietic system; ? Suspected history of alcohol and drug abuse, or other situations that reduce the possibility of enrollment or complicate enrollment according to the judgment of the researcher, such as frequent changes in the working environment, which is easy to cause loss of follow-up; ? Subjects who have participated or are participating in clinical trials of other drugs within 4 weeks.

Design outcomes

Primary

MeasureTime frame
ESSPRI;

Secondary

MeasureTime frame
TCM syndrome score;Exocrine gland function index;Laboratory indicators(IgA\G\M,C3\C4,ESR,CRP,RF,IL6);ESSDAI;

Countries

China

Contacts

Public ContactKou Qiuai
kouqiuai@163.com13910527397

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026